Business Context and Reporting Period
Company: Oncolytics Biotech Inc.
Filing Type: Form 20-F (Annual Report)
Reporting Period: Fiscal year ended December 31, 2012
Accounting Standards: International Financial Reporting Standards (IFRS)
Business Overview: Oncolytics is a development-stage biopharmaceutical company focused on the discovery and development of REOLYSIN®, a therapeutic reovirus designed to treat cancers with an activated Ras pathway. The company has no commercial product sales and relies on equity financing to fund research and development (R&D).
Key Financial Metrics
| Metric (CAD) | 2012 | 2011 | 2010 |
|---|---|---|---|
| Revenues | $0 | $0 | $0 |
| Net Loss | $(36,373,521) | $(29,044,701) | $(24,659,061) |
| Loss Per Share (Basic & Diluted) | $(0.48) | $(0.41) | $(0.39) |
| Total Assets | $22,078,090 | $36,024,617 | $44,432,442 |
| Cash and Cash Equivalents | $19,323,541 | $32,918,751 | $39,296,682 |
| Short-Term Investments | $1,969,228 | $1,936,787 | $0 |
| Working Capital | $14,377,532 | $29,128,268 | $N/A |
| Shareholders' Equity | $14,786,780 | $29,520,379 | $36,394,960 |
| Accumulated Deficit | $(207,814,353) | $(171,440,832) | $(142,396,131) |
Note: All figures are in Canadian Dollars (CAD) unless otherwise specified. The company reported no debt other than trade accounts payable.
Material Changes vs. Prior Period
- Increased Net Loss: Net loss increased by approximately 25% to $36.4 million in 2012 compared to $29.0 million in 2011, driven primarily by higher R&D expenses.
- R&D Expenses: Research and development costs rose significantly to $31.4 million in 2012 from $23.4 million in 2011, reflecting the expansion of the clinical trial program for REOLYSIN®.
- Cash Position: Cash and cash equivalents decreased by approximately $13.6 million to $19.3 million, despite a public offering in 2012. This decline was due to high operating cash burn ($34.3 million used in operating activities).
- Equity Financing: The company issued 5,065,750 common shares in a bought deal financing in February 2012, generating net cash proceeds of approximately $19.8 million (gross proceeds of $21.3 million).
- Share Count: Outstanding common shares increased to 76,710,285 as of December 31, 2012, from 71,251,335 in 2011.
Guidance, Outlook, Risks, and Contingencies
Outlook and Guidance
Management anticipates continuing to incur significant losses in 2013 and the foreseeable future. The company does not expect to reach profitability until after the successful commercialization of REOLYSIN®. Future capital requirements will depend on the progress of clinical trials, regulatory approvals, and the ability to secure strategic partnerships or additional financing.
Key Risks
- Development Risk: REOLYSIN® is in the research and development stage. There is no assurance that clinical trials will demonstrate safety and efficacy or that regulatory approval will be obtained.
- Liquidity Risk: The company requires additional financing to fund ongoing operations. Failure to secure capital could force a reduction in R&D expenditures or delay clinical trials.
- Manufacturing Risk: The company relies on third-party contract manufacturers for REOLYSIN® production. Disruptions or scaling issues could delay trials.
- Regulatory Risk: Intense regulatory scrutiny by the FDA, Health Canada, and other agencies could delay or prevent marketing approval.
- PFIC Status: The company believes it is a Passive Foreign Investment Company (PFIC) for U.S. tax purposes, which may have adverse tax consequences for U.S. shareholders.
Contingencies and Commitments
- Clinical Trial Commitments: The company is committed to payments totaling $8.6 million in 2013 for clinical trial activities and collaborations.
- Contingent Milestone Payment: A $1.0 million milestone payment is outstanding to former shareholders, payable within 90 days of the first regulatory marketing approval for REOLYSIN®.
- Royalties: The company has obligations to pay royalties to the Alberta Cancer Board and the Biotechnology Research Institute (BRI) contingent upon future sales revenue.
Investor Verification Checklist
- Cash Runway: Verify the current cash balance against the $8.6 million committed for 2013 clinical trials to assess the immediate need for additional financing.
- Clinical Trial Status: Review the latest status of the 14+ ongoing clinical trials (Phase I, II, and III) listed in the filing to gauge progress toward regulatory approval.
- Financing History: Note the February 2013 subsequent event where the company closed an underwritten public offering of 8,000,000 shares at US$4.00 for gross proceeds of $32 million.
- Share Dilution: Monitor the impact of the 2012 and 2013 equity issuances on existing shareholder ownership percentages.
- Regulatory Milestones: Track the timeline for the Phase III trial (REO 018) for squamous cell carcinoma of the head and neck, as this is a critical step toward commercialization.